Myasthenia gravis is a rare disease where the immune system attacks the communication between nerves and muscles, causing weakness. It often affects the muscles used for eye movement, facial ...

Presentations to highlight JADE101’s preclinical safety profile and translational framework guiding its clinical development ...

Self-administration of rozanolixizumab, a neonatal Fc receptor blocker (FcRn) indicated for generalized myasthenia gravis, ...

A novel drug for systemic lupus erythematosus (SLE) first developed in China, and approved there since 2021, did well enough in a new placebo-controlled phase III trial that approval in Western ...

Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on ...

RAPT Therapeutics, Inc. ( NASDAQ: RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria October 20, 2025 8:30 AM EDT Good morning, and welcome to RAPT's conference ...

Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases ...

First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multiple myeloma as early as second line ...

Novo Nordisk NVO and Omeros Corporation OMER have announced the signing of a definitive asset purchase and license agreement ...

MSD's cancer immunotherapy Keytruda will soon be available as a subcutaneous injection that does away with the need to visit an infusion clinic. Keytruda Qlex (pembrolizumab and berahyaluronidase alfa ...

July 2025: Taiho Oncology and Taiho Pharmaceutical announced the FDA’s acceptance of a supplemental New Drug Application for ...